Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment.

The effect of droloxifene (3-hydroxytamoxifen) given as first-line endocrine treatment was evaluated in 39 postmenopausal women with advanced receptor-positive or receptor-unknown breast cancer. The patients had not received any previous anticancer therapy apart from adjuvant treatment. The overall response rate (CR + PR) was 51% (8% CR, 43% PR), 95% confidence interval+/-15.7%. Median time to progression (all patients) was 8 months, the median time to response 2 months, while the median duration of response was 10 months. The drug was well tolerated with no major side effects recorded; 16% of the patients experienced hot flushes. The response to droloxifene recorded in the present study is in accordance with the response rates to tamoxifen as first-line treatment in identical groups of patients.

[1]  R. Gelber,et al.  Endocrine therapies of breast cancer. , 1996, Seminars in oncology.

[2]  P. Lønning,et al.  Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. , 1995, The Journal of endocrinology.

[3]  G. Hortobagyi,et al.  Use of tamoxifen for breast cancer: twenty-eight years later. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  V. Jordan,et al.  Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. , 1995, Annual review of pharmacology and toxicology.

[5]  V. Jordan.  A current view of tamoxifen for the treatment and prevention of breast cancer , 1993 .

[6]  P. Bruning,et al.  Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. , 1992, European journal of cancer.

[7]  U. Eppenberger,et al.  Pharmacologic and Biologic Properties of Droloxifene, A New Antiestrogen , 1991, American journal of clinical oncology.

[8]  K. Pollow,et al.  Pharmacokinetics of Droloxifene and Its Metabolites in Breast Cancer Patients , 1991, American journal of clinical oncology.

[9]  P. Lønning.  New endocrine drugs for treatment of advanced breast cancer. , 1990, Acta oncologica.

[10]  H. Mouridsen,et al.  Endocrine therapy of advanced breast cancer. , 1988, Acta oncologica.

[11]  U. Eppenberger,et al.  Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7. , 1983, Journal of the National Cancer Institute.

[12]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.